Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) Director Jack Schuler bought 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was purchased at an average price of $24.47 per share, for a total transaction of $367,050.00. Following the transaction, the director owned 555,810 shares of the company’s stock, valued at $13,600,670.70. The trade was a 2.77% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Biodesix Price Performance
Shares of NASDAQ:BDSX opened at $24.00 on Friday. Biodesix, Inc. has a twelve month low of $5.26 and a twelve month high of $25.52. The company’s 50 day moving average is $20.50 and its 200 day moving average is $16.19. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 5.12. The company has a market cap of $253.20 million, a PE ratio of -7.57 and a beta of 0.56.
Biodesix (NASDAQ:BDSX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The company had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million. On average, sell-side analysts forecast that Biodesix, Inc. will post -2.68 EPS for the current year.
Institutional Investors Weigh In On Biodesix
Wall Street Analyst Weigh In
Several research analysts recently issued reports on BDSX shares. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. Canaccord Genuity Group increased their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Roth Capital initiated coverage on Biodesix in a research note on Wednesday, June 24th. They set a “buy” rating and a $32.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Biodesix has an average rating of “Moderate Buy” and a consensus price target of $31.33.
View Our Latest Stock Analysis on Biodesix
Biodesix Company Profile
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Featured Articles
- Five stocks we like better than Biodesix
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
